Skip to main content

Advertisement

Table 3 Multivariate analysis results

From: Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma

  Number Relative risk 95%CI
lower limit
95%CI
upper limit
p value
Acute GVHD (grades 2–4)a      
 Non-rituximab RIC 1004 1    0.43
 Rituximab-containing RIC 377 1.14 0.83 1.56  
Acute GVHD (grades 3–4)a      
 Non-rituximab RIC 1004 1    0.54
 Rituximab-containing RIC 377 1.16 0.72 1.89  
Chronic GVHD      
 Non-rituximab RIC 982 1    0.22
 Rituximab-containing RIC 369 1.15 0.92 1.46  
Non-relapse mortality      
 Non-rituximab RIC 988 1    0.51
 Rituximab-containing RIC 367 0.90 0.67 1.22  
Progression/relapse      
 Non-rituximab RIC 988 1    0.055
 Rituximab-containing RIC 367 0.79 0.63 1.01  
PFS      
 Non-rituximab RIC 988 1    0.006
 Rituximab-containing RIC 367 0.76 0.62 0.92  
Mortality      
 Non-rituximab RIC 1022 1    0.08
 Rituximab-containing RIC 379 0.84 0.69 1.02  
  1. Abbreviations: GVHD graft-versus-host disease, CI confidence interval, RIC reduced-intensity conditioning
  2. aAcute GVHD models used logistic regression